COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02228525
Recruitment Status : Active, not recruiting
First Posted : August 29, 2014
Last Update Posted : April 7, 2020
M.D. Anderson Cancer Center
Columbia University
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center